FATE News and Press, Fate Therapeutics Inc. From 08/19/20

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Edward Dulac has been appointe...

Image source: The Motley Fool. Fate Therapeutics Inc   (NASDAQ: FATE) Q2 2020 Earnings Call Aug 5, 2020 , 5:30 p.m. ET Operator Continue reading

Fate Therapeutics, Inc. (FATE) Q2 2020 Earnings Conference Call August 05, 2020 5:30 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Dan Shoemaker - Chief Scientific Officer Bob Valamehr - Chief Development Officer Wayne Chu - Senior Vice Pres...

Fate Therapeutics (NASDAQ: FATE ) : Q2 GAAP EPS of -$0.35 misses by $0.10 . More news on: Fate Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Partial Response Reported with FT596 Monotherapy at First Dose Level in Refractory DLBCL Patient Enrollment Initiated with FT596 in Combination with Rituximab for B-cell Lymphoma  IND Cleared for FT538, the First CRISPR-edited, iPSC-derived Cell Therapy, for AML and Multiple ...

SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker, Ph.D., Chief Scientific Of...

SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call a...

Vertex ( VRTX ), the inventor of the new cystic fibrosis wonder drug Trikafta, is a shining star amongst biotech and pharmaceuticals for 2020. On a background of strong fundamentals, with forecasted EBITDA growth of 51.29% in the coming year just to name a few, investors have demonstrated an e...

As a clinical-stage immunotherapy company, Fate Therapeutics (NASDAQ: FATE) has a long way to go before it has recurring revenue, but it could make a few millionaires in the meantime. Thanks to its powerful platform that enables the efficient mass production of high-impact and high-complexit...

As 2020 has demonstrated, the stock market can move in any direction in the short term. But as historical stock market data suggest, the stock market wields rock-solid wealth-building potential in the long run. That's why individual investors are best served by adopting a long-term mindset with ...